Next Article in Journal
A Case of Nivolumab-Induced Acute-Onset Type 1 Diabetes Mellitus in Melanoma
Previous Article in Journal
Extended Venous Thromboembolism Prophylaxis after Abdominopelvic Cancer Surgery: A Retrospective Review
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 1
10.3747/co.26.4151
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors

by
V. Venetsanaki
1,*,
Anastasios Boutis
1,*,
A. Chrisoulidou
2 and
P. Papakotoulas
1
1
First Department of Clinical Oncology, Theagenio Hospital, 54007 Thessaloniki, Greece
2
Department of Endocrinology, Theagenio Hospital, 54007 Thessaloniki, Greece
*
Authors to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(1), 111-114; https://doi.org/10.3747/co.26.4151
Submission received: 3 November 2018 / Revised: 6 December 2018 / Accepted: 11 January 2019 / Published: 1 February 2019

Abstract

Cancer immunotherapy has been one of the highlights in the advancement of cancer care. Certain immune checkpoint inhibitors bind to PD-1 on T cells and mediate an antitumour immune response. Given that immune checkpoint inhibitors are becoming part of standard care, a new class of adverse events—immune-related adverse events—has emerged. Among them is endocrine toxicity, most commonly targeting the thyroid, pituitary, or adrenal glands. New-onset diabetes mellitus has been reported in fewer than 1% of patients. We present a patient with type 1 diabetes mellitus secondary to immunotherapy, together with an overview of the associated literature. Patients who develop type 1 diabetes mellitus experience a rapid course, and diabetic ketoacidosis is commonly the presenting symptom. Insulin is currently the treatment of choice; oral antidiabetics or corticosteroids do not assist in management. Several predictive factors are under investigation, but physician awareness and prompt management are key to a positive outcome.
Keywords: immune checkpoint inhibitors; diabetes mellitus; immunotherapy; immune-related adverse events; irAEs; nivolumab immune checkpoint inhibitors; diabetes mellitus; immunotherapy; immune-related adverse events; irAEs; nivolumab

Share and Cite

MDPI and ACS Style

Venetsanaki, V.; Boutis, A.; Chrisoulidou, A.; Papakotoulas, P. Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors. Curr. Oncol. 2019, 26, 111-114. https://doi.org/10.3747/co.26.4151

AMA Style

Venetsanaki V, Boutis A, Chrisoulidou A, Papakotoulas P. Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors. Current Oncology. 2019; 26(1):111-114. https://doi.org/10.3747/co.26.4151

Chicago/Turabian Style

Venetsanaki, V., Anastasios Boutis, A. Chrisoulidou, and P. Papakotoulas. 2019. "Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors" Current Oncology 26, no. 1: 111-114. https://doi.org/10.3747/co.26.4151

APA Style

Venetsanaki, V., Boutis, A., Chrisoulidou, A., & Papakotoulas, P. (2019). Diabetes Mellitus Secondary to Treatment with Immune Checkpoint Inhibitors. Current Oncology, 26(1), 111-114. https://doi.org/10.3747/co.26.4151

Article Metrics

Back to TopTop